Belantamab mafodotin ( DrugBank: Belantamab mafodotin )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 28 | 全身性アミロイドーシス | 7 |
28. 全身性アミロイドーシス
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05145816 (ClinicalTrials.gov) | August 1, 2023 | 23/11/2021 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | AL Amyloidosis;Amyloidosis | Drug: Belantamab mafodotin 2.5 mg/kg (6 weeks);Drug: Belantamab mafodotin 2.5 mg/kg (4 weeks);Drug: Belantamab mafodotin 2.5 mg/kg (8 weeks);Drug: Belantamab mafodotin 1.9 mg/kg (8 weeks);Drug: Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | University of Texas Southwestern Medical Center | GlaxoSmithKline | Not yet recruiting | 18 Years | N/A | All | 37 | Phase 1/Phase 2 | United States |
| 2 | EUCTR2020-004001-32-NL (EUCTR) | 24/06/2021 | 29/01/2021 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Germany;Netherlands;United Kingdom;Italy | ||
| 3 | EUCTR2020-004001-32-IT (EUCTR) | 03/05/2021 | 02/08/2021 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis. - EMN27 | Relapsed or refractory AL amyloidosis. MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Belantamab mafodotin Product Code: [GSK2857916] INN or Proposed INN: belantamab mafodotin | STICHTING EUROPEAN MYELOMA NETWORK | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Netherlands;Germany;United Kingdom;Italy | ||
| 4 | EUCTR2020-004001-32-DE (EUCTR) | 27/04/2021 | 04/12/2020 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Netherlands;Germany;United Kingdom;Italy | ||
| 5 | NCT04617925 (ClinicalTrials.gov) | February 26, 2021 | 20/10/2020 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | AL Amyloidosis | Drug: Belantamab mafodotin | European Myeloma Network | GlaxoSmithKline | Recruiting | 18 Years | N/A | All | 35 | Phase 2 | France;Germany;Greece;Italy;Netherlands;United Kingdom |
| 6 | EUCTR2020-004001-32-FR (EUCTR) | 29/01/2021 | 03/12/2020 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Netherlands;Germany;United Kingdom;Italy | ||
| 7 | EUCTR2020-004001-32-GR (EUCTR) | 15/01/2021 | 04/12/2020 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Germany;Netherlands;United Kingdom;Italy |